Clinical Trial Update: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CPI-613 (devimistat) in combination with cytarabine and mitoxantrone hydrochloride for relapsed or refractory acute myeloid leukemia ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPI-613 (devimistat)
• CYTARABINE (CYTARABINE)
• Mitoxantrone hydrochloride (mitoxantrone)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Status: COMPLETED